These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 35937991)

  • 1. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 2. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
    Ma C; Bao Y; Xu J; Xiao B; Li H
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
    Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
    Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
    BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.
    Yang J; Wu Z; Wu X; Chen S; Xia X; Zeng J
    Front Oncol; 2022; 12():1050288. PubMed ID: 36620557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ligamentum flavum hypertrophy based on m6A RNA methylation modification and the immune microenvironment.
    He Z; Zhu Z; Tang T; Guo P; Gao M; Li B; Nguyen TCT; Chen H; Liu X; Zhou Z; Liu S
    Am J Transl Res; 2022; 14(12):8800-8827. PubMed ID: 36628248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
    Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
    Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
    Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
    Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
    Bai Z; Wang X; Zhang Z
    Front Genet; 2022; 13():655169. PubMed ID: 35281815
    [No Abstract]   [Full Text] [Related]  

  • 13. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
    Xu LC; Pan JX; Pan HD
    Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma.
    Pan J; Xu L; Pan H
    Front Oncol; 2020; 10():1444. PubMed ID: 32974164
    [No Abstract]   [Full Text] [Related]  

  • 16. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
    Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
    Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
    Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
    BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
    Li Y; Li X; Yu Z
    Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.